Join our distinguished panel of experts, Drs Yasir Elamin and Kaushal Parikh, for an engaging discussion on recent key data on ALK-positive advanced NSCLC. This session, which includes expert commentary on clinical implications from oral and poster presentations at ASCO, ESMO, and WCLC 2023, focuses on the use of circulating tumor DNA (ctDNA), the combination of local consolidative therapy with an ALK-TKI (i.e., the BRIGHTSTAR study)and the impact of quality of life on treatment decisions in patients with ALK-positive advanced NSCLC. 

Medscape © 2024 WebMD Medical Affairs Services, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Supported by Takeda Oncology Medical Affairs. Takeda provided input on the topic choice and funding support to produce content. Content was reviewed for scientific accuracy by Takeda Medical colleagues. Views expressed by faculty are their own.

This Alexion-sponsored educational podcast is intended for US healthcare professionals only.

Care of patients with neurofibromatosis type 1 (NF1) is complex and involves numerous specialists, due to the varying manifestations and locations of the condition. Join Prof Bruce Korf and Dr Amy Armstrong in this podcast, the last one of the series, for an engaging discussion regarding the multidisciplinary approach to care in patients with NF1. Our experts provide insights into the value of multidisciplinary care teams (especially for patients with NF1-related plexiform neurofibromas), the way they collaborate within these teams in their clinical practice, and the current gaps. The podcast concludes with an outlook for the future multidisciplinary approach to care for these patients.

This Alexion-sponsored educational podcast is intended for US healthcare professionals only.

Neurofibromatosis type 1 (NF1) can create a substantial quality of life burden on patients and their caregivers, and the experience and resilience of each individual patient varies. Of importance is the increased risk for psychosocial and emotional difficulties, such as anxiety, depression, and social withdrawal. This requires special attention at all stages of the condition.

Join Drs. Bruce Korf and Karin Walsh as they discuss the psychological impact associated with NF1, the challenges experienced by the multidisciplinary teams and NF clinics involved in treatment and care of the condition, and potential solutions for these challenges.

MM/US/DISEASE/1191 October 2023

This Alexion-sponsored educational podcast is intended for US healthcare professionals only.

Neurofibromatosis type 1 (NF1) is a disorder of heterogeneity, and signs and symptoms can vary widely from patient to patient. International consensus recommendations, updated in 2021, incorporate a revised diagnostic criteria for NF1 with new clinical features and molecular diagnosis.

This podcast, one of the series, provides insights into the key diagnostic considerations of NF1. Join Drs Bruce Korf and Carlos Guillermo Romo as they talk about the practical aspects and challenges of the diagnostic process in NF1. Our experts outline the 2021 diagnostic criteria and provide an overview of the symptoms associated with NF1, discussing diagnostic genetic testing, differential diagnosis, and primary care referrals to an NF1 specialist. Additionally, the podcast dives into challenging clinical scenarios with insightful expert commentary.

MM/US/DISEASE/1151

How can Medical Affairs divisions bring greater value to their organizations and practitioners every day?

What is so different about Medscape Medical Affairs in this crowded Medical Communications landscape?